Victory Capital Management
RNAC icon

Victory Capital Management’s Cartesian Therapeutics RNAC Stock Holding History

Victory Capital Management’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-453
Closed -$8.84K – 2528
2024
Q1 		$8.84K Sell
453
-49
-10% -$1.04K ﹤0.01% 2465
2023
Q4 		$10.4K Buy
502
+97
+24% +$2.9K ﹤0.01% 2528
2023
Q3 		$12.9K Buy
405
+31
+8% +$1.04K ﹤0.01% 2471
2023
Q2 		$12.6K Sell
374
-9
-2% -$322 ﹤0.01% 2476
2023
Q1 		$16K Sell
383
-16
-4% -$752 ﹤0.01% 2522
2022
Q4 		$13.5K Hold
399
– – ﹤0.01% 2532
2022
Q3 		$20K Sell
399
-170
-30% -$9.34K ﹤0.01% 2628
2022
Q2 		$22K Buy
569
+35
+7% +$1.04K ﹤0.01% 2608
2022
Q1 		$12K Buy
534
+127
+31% +$7.94K ﹤0.01% 2671
2021
Q4 		$40K Sell
407
-7
-2% -$753 ﹤0.01% 2656
2021
Q3 		$52K Sell
414
-8
-2% -$966 ﹤0.01% 2684
2021
Q2 		$53K Sell
422
-17
-4% -$2.02K ﹤0.01% 2661
2021
Q1 		$60K Sell
439
-13
-3% -$1.61K ﹤0.01% 2653
2020
Q4 		$41K Sell
452
-19
-4% -$1.65K ﹤0.01% 2470
2020
Q3 		$35K Buy
+471
New +$36.1K ﹤0.01% 2401
2020
Q2 		– Sell
-369
Closed -$26K – 3131
2020
Q1 		$26K Buy
+369
New +$35.6K ﹤0.01% 3013
2019
Q4 		– Sell
-242
Closed -$13K – 3152
2019
Q3 		$13K Buy
+242
New +$12.9K ﹤0.01% 3178

Other funds holding RNAC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Victory Capital Management's RNAC Position: Q2 2024 in Review

Victory Capital Management sold out of Cartesian Therapeutics (RNAC) in Q2 2024, closing a stake of 453 shares — an estimated $8.84K sold.

Victory Capital Management first reported a position in RNAC in Q3 2019 and held it in 17 quarters. The position peaked at $60K in Q1 2021. 61 funds tracked by Wall St. Rank hold RNAC as of Q2 2024.

  • Victory Capital Management reported no remaining Cartesian Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Victory Capital Management sold 453 Cartesian Therapeutics shares in Q2 2024, an estimated $8.84K.
  • Victory Capital Management first reported a position in Cartesian Therapeutics in Q3 2019 and held it in 17 quarters.
  • Victory Capital Management's Cartesian Therapeutics position peaked at $60K in Q1 2021.
  • 61 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2024.

Based on Victory Capital Management's 13F filing for Q2 2024, filed 5 Aug 2024.